Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Dementia Consortium

- PMLiVE

Eliquis and Ryzodeg feature among Japan’s year-end approvals

Actonel and Neupro also given green light

EISAI

Eisai forms neurology partnership with UCL

Unique ‘therapeutic innovation group’ will research Alzheimer's, Parkinson's and other brain conditions

- PMLiVE

Lundbeck and Takeda submit depression drug for US approval

Brintellix could help Lundbeck overcome loss of patent protection for Lexapro/Cipralex

- PMLiVE

Funding boost for late-stage tau-based Alzheimer’s research

Singapore company TauRx receives $112m investment to take LMTX treatment into phase III

- PMLiVE

Interview: Trevor Smith, Takeda

Takeda’s head of commercial operations for Europe and Canada talks about the integration of Nycomed and European market access

- PMLiVE

Takeda acquires US-based drug discovery company Envoy

Japanese pharma firm gains target identification technology and preclinical CNS assets

- PMLiVE

Acquisitions soften Actos blow in Takeda’s first-half results

URL Pharma and Nycomed purchases help sales increase 12 per cent to 787bn yen

Pharma must ’embrace the new reality’ and meet payers’ needs

This means capturing better health economic data during product development, says Takeda's Trevor Smith

- PMLiVE

Takeda pays $60m for vaccine company LigoCyte

Gains first-in-class norovirus candidate and new vaccine platform

Evotec CEO Werner Lanthaler temporarily stands down

Cites health reasons

- PMLiVE

Takeda completes new manufacturing facility in Russia

Expands Japanese firm’s presence in key emerging market

FDA sued for approving high dose of Eisai’s Alzheimer’s drug Aricept

Consumer rights group Public Citizen claims the high-strength dose is unsafe

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links